The hearings come as part of an 18-month investigation first led by the late Rep. Elijah Cummings, D-Md., in 2019.
Below are the six drugs the committee included in its probe, according to STAT:
- Revlimid, a multiple myeloma drug manufactured by Bristol Myers Squibb
- Copaxone, a multiple sclerosis drug manufactured by Teva
- Enbrel, an autoimmune disease drug manufactured by Amgen
- Sensipar, a secondary hyperparathyroidism drug manufactured by Amgen
- H.P. Acthar, hormone gel manufactured by Mallinckrodt
- Gleevec, a chemotherapy drug manufactured by Novartis
More articles on pharmacy:
10 recent exec moves affecting the pharma industry
Pfizer to give $22M in drugs to Strategic National Stockpile
7 former FDA commissioners write opinion column lamenting White House’s treatment of agency
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
